Efficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Thorax

• Publication date

  2015-10-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/thoraxjnl-2014-206732PMID 26490732
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)

  2015cited by this paper
• Comparative efficacy of long-acting muscarinic antagonists in preventing COPD exacerbations: a network meta-analysis and meta-regression

  2015cited by this paper
• Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.

  2015cited by this paper
• Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial.

  2014cited by this paper
• Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report.

  2014cited by this paper
• Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study

  2014cited by this paper
• Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study.

  2014cited by this paper
• Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.

  2014cited by this paper
• Efficacy and safety of combining olodaterol Respimat® and tiotropium HandiHaler® in patients with COPD: results of two randomized, double-blind, active-controlled studies

  2014cited by this paper
• Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD – role of umeclidinium/vilanterol

  2014cited by this paper
• Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study

  2014cited by this paper
• Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study

  2014cited by this paper
• Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study

  2014cited by this paper
• The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects

  2013cited by this paper
• Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study

  2013cited by this paper
• Evidence Synthesis for Decision Making 4

  2013cited by this paper
• “All I want for Christmas is Two”: The Advent of Novel Fixed-Combination Inhalers for COPD and Outlook for 2014

  2013cited by this paper
• Evidence Synthesis for Decision Making 2

  2013cited by this paper
• Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study.

  2013cited by this paper
• The MABA approach: a new option to improve bronchodilator therapy

  2013cited by this paper
• Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.

  2013cited by this paper
• Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.

  2013cited by this paper
• Evidence Synthesis for Decision Making Inconsistency in Networks of Evidence Based on Randomized Controlled Trials.

  2013cited by this paper
• Evidence Synthesis for Decision Making 3

  2013cited by this paper
• Meta-Analysis of Rare Binary Adverse Event Data

  2012cited by this paper
• Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease.

  2012cited by this paper
• Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison

  2012cited by this paper
• Sample size and power considerations in network meta-analysis

  2012cited by this paper
• The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials

  2011cited by this paper
• Heterogeneity: Subgroups, Meta-Regression, Bias And Bias-Adjustment

  2011cited by this paper
• Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial.

  2011cited by this paper
• Direct costs of chronic obstructive pulmonary disease among managed care patients

  2010cited by this paper
• Formoterol and Tiotropium Compared With Tiotropium Alone for Treatment of COPD

  2009cited by this paper
• Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study.

  2008cited by this paper
• Tiotropium in Combination with Placebo, Salmeterol, or Fluticasone-Salmeterol for Treatment of Chronic Obstructive Pulmonary Disease: A Randomized Trial

  2008cited by this paper
• Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.

  2007cited by this paper
• Tiotropium in Combination with Placebo, Salmeterol, or FluticasoneSalmeterol for Treatment of Chronic Obstructive Pulmonary Disease

  2007cited by this paper
• Assessing the convergence of Markov Chain Monte Carlo methods: an example from evaluation of diagnostic tests in absence of a gold standard.

  2007cited by this paper
• Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.

  2007cited by this paper
• Combination of direct and indirect evidence in mixed treatment comparisons

  2004cited by this paper
• Minimal important difference of the transition dyspnoea index in a multinational clinical trial

  2003cited by this paper
• Bayesian measures of model complexity and fit

  2002cited by this paper
• Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD.

  1999cited by this paper

• Dual combination therapy versus long‐acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta‐analysis

  2025cites this paper
• A Delphi Consensus Project to Capture Greek Experts’ Opinion on the Position of Triple Therapies in COPD: Why, When and to Whom

  2025cites this paper
• Pharmacological management of COPD.

  2025cites this paper
• Benefit of dual bronchodilator therapy on exacerbations in former and current smokers with chronic obstructive pulmonary disease in real-world clinical practice: a multicenter validation study (TOReTO)

  2024cites this paper
• How can the findings of the EMAX trial on long-acting bronchodilation in chronic obstructive pulmonary disease be applied in the primary care setting?

  2023cites this paper
• 2023 Canadian Thoracic Society Guideline on Pharmacotherapy in Patients with Stable COPD

  2023cites this paper
• Differential Response to 12 Weeks of Once-Daily Tiotropium/Olodaterol Fixed Dose Combination in Patients with COPD: A Multidimensional Response Profiling in the TORRACTO Study

  2023cites this paper
• Cardiovascular Diseases in COPD: From Diagnosis and Prevalence to Therapy

  2023cites this paper
• Pharmacological therapy for stable chronic obstructive pulmonary disease

  2023cites this paper
• Inhaled corticosteroids administration/withdrawal as a therapeutic continuum for patients with chronic obstructive pulmonary disease in real clinical practice

  2023cites this paper
• The Bronchoprotective Effects of Dual Pharmacology, Muscarinic Receptor Antagonist and β2 Adrenergic Receptor Agonist Navafenterol in Human Small Airways

  2023cites this paper
• Prevalence of abnormal spirometry in individuals with a smoking history and no known obstructive lung disease.

  2023cites this paper
• Best Practice Management of Patients With Chronic Obstructive Pulmonary Disease: A Case-Based Review

  2022cites this paper
• Diagnosis and general approaches to the treatment of chronic obstructive pulmonary disease

  2022cites this paper
• Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis

  2022cites this paper
• Characteristics of Patients with Chronic Obstructive Pulmonary Disease Treated with Long-Acting Bronchodilators in a Real-World Setting in Singapore: A Single-Center Observational Study

  2022cites this paper
• Applying key learnings from the EMAX trial to clinical practice and future trial design in COPD.

  2022cites this paper
• Limitations of a 6-min walk test to assess the efficacy of menthol for breathlessness

  2022cites this paper
• Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials.

  2021cites this paper
• The role of long-acting muscarinic antagonist/long-acting β agonist fixed-dose combination treatment for chronic obstructive pulmonary disease in China: a narrative review

  2021cites this paper
• Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model

  2021cites this paper
• l-Menthol – a new treatment for breathlessness?

  2021cites this paper
• Real-World Effectiveness of Inhalation Therapy Among Patients With Symptomatic COPD in China: A Multicenter Prospective Study

  2021cites this paper
• Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX Trial

  2021cites this paper
• Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-Naïve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX Trial

  2021cites this paper
• Future concepts in bronchodilation for COPD: dual- versus monotherapy

  2021cites this paper
• Effects of cigarette smoke exposure on pulmonary physiology, muscle strength and exercise capacity in a retrospective cohort with 30,000 subjects

  2021cites this paper
• The Effectiveness of 3 Combined Therapeutic Regimens in Egyptian Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: A Randomized Double-Blind Prospective Pilot Study

  2021cites this paper
• Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD

  2021cites this paper
• Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β2-agonist bronchodilators

  2020cites this paper
• Pharmacology of Acetylcholine and Cholinergic Receptors

  2020cites this paper
• Comparisons of exacerbations and mortality among LAMA/LABA combinations in stable chronic obstructive pulmonary disease: systematic review and Bayesian network meta-analysis

  2020cites this paper
• Impact of baseline COPD symptom severity on the benefit from dual versus mono-bronchodilators: an analysis of the EMAX randomised controlled trial

  2020cites this paper
• Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO® Trials

  2020cites this paper
• Comparaciones entre asociaciones de broncodilatadores de larga duración para la enfermedad pulmonar obstructiva crónica

  2020cites this paper
• LABA/LAMA fixed-dose combinations versus LAMA monotherapy in the prevention of COPD exacerbations: a systematic review and meta-analysis

  2020cites this paper
• Early and sustained symptom improvement with umeclidinium/vilanterol versus monotherapy in COPD: a post hoc analysis of the EMAX randomised controlled trial

  2020cites this paper
• Glycopyrrolate/formoterol fumarate metered dose inhaler for maintenance-naïve patients with chronic obstructive pulmonary disease: a post-hoc analysis of the randomized PINNACLE trials

  2020cites this paper
• Incorporating new evidence on inhaled medications in COPD. The latin American chest association (ALAT) 2019

  2020cites this paper
• Pharmacotherapy for chronic obstructive pulmonary disease

  2019cites this paper
• Diagnosis and Outpatient Management of Chronic Obstructive Pulmonary Disease: A Review

  2019cites this paper
• A Randomized Trial of Dual-Acting Bronchodilator AZD8871 for Chronic Obstructive Pulmonary Disease.

  2019cites this paper
• SEPAR ’ s voice Spanish COPD Guidelines ( GesEPOC ) 2017 . Pharmacological Treatment of Stable Chronic Obstructive Pulmonary Disease

  2019cites this paper
• Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis

  2019cites this paper
• The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects

  2019cites this paper
• Patient-Reported Burden of Illness in a Prevalent COPD Population Treated with Long-Acting Muscarinic Antagonist Monotherapy: A Claims-Linked Patient Survey Study

  2019cites this paper
• Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD

  2019cites this paper
• Update on management of stable chronic obstructive pulmonary disease.

  2019cites this paper
• Economic Impact of Reducing Inappropriate Inhaled Corticosteroids Use in Patients With Chronic Obstructive Pulmonary Disease: ISPOR's Guidance on Budget Impact in Practice.

  2019cites this paper
• New therapeutic targets for the prevention of infectious acute exacerbations of COPD: role of epithelial adhesion molecules and inflammatory pathways.

  2019cites this paper
• Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial

  2019cites this paper
• Canadian Thoracic Society Clinical Practice Guideline on pharmacotherapy in patients with COPD – 2019 update of evidence

  2019cites this paper
• Incorporating New Evidence on Inhaled Medications in COPD. The Latin American Chest Association (ALAT) 2019.

  2019cites this paper
• Impact on survival of combination inhalers in patients with COPD at high risk of cardiovascular events.

  2019cites this paper
• Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal

  2018cites this paper
• Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.

  2018cites this paper
• Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD).

  2018cites this paper
• The Cholinergic Pathways in Inflammation: A Potential Pharmacotherapeutic Target for COPD

  2018cites this paper
• LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review

  2018cites this paper
• New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology

  2018cites this paper
• Systematic literature review and meta-analysis of US-approved LAMA/LABA therapies versus tiotropium in moderate-to-severe COPD

  2018cites this paper
• Risk of Severe Cardiovascular Events From Add‐On Tiotropium in Chronic Obstructive Pulmonary Disease

  2018cites this paper
• Efficacy of Umeclidinium/Vilanterol in Elderly Patients with COPD: A Pooled Analysis of Randomized Controlled Trials

  2018cites this paper
• Pharmacotherapy for chronic obstructive pulmonary disease

  2018cites this paper
• Pharmacoeconomic Analysis of Drug Therapy of Chronic Obstructive Pulmonary Disease: Umeclidinium Bromide/Vilanterol Compared with other Combinations of Long-Acting β-Antagonists and Anticholinergics

  2018cites this paper
• Prevention of copd exacerbations. Focus on dual bronchodilators

  2018cites this paper
• A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD

  2018cites this paper
• Профилактика обострений хронической обструктивной болезни легких. В фокусе – двойные комбинации бронхолитиков

  2018cites this paper
• Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol in Maintenance-Naïve Patients with Moderate Symptomatic Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis

  2018cites this paper
• COPD treatment pathways in France: a retrospective analysis of electronic medical record data from general practitioners

  2018cites this paper
• Understanding shared pathogenesis between chronic obstructive pulmonary disease (COPD) and lung cancer by means of cell specific genomics

  2018cites this paper
• LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review

  2018cites this paper
• Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.

  2018cites this paper
• Efficacy and Safety of Long-acting Beta-2 Agonist and Long-acting Muscarinic Antagonist Combinations in Patients with Chronic Obstructive Pulmonary Disease: Meta-analysis of Phase 3 Randomized Trials

  2018cites this paper
• Guía española de la enfermedad pulmonar obstructiva crónica (GesEPOC) 2017. Tratamiento farmacológico en fase estable

  2017cites this paper
• Recommendations for the pharmacological treatment of COPD: questions and answers

  2017cites this paper
• Impact du sevrage des corticostéroïdes inhalés dans la BPCO

  2017cites this paper
• Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study

  2017cites this paper
• Symptom variability and control in COPD: Advantages of dual bronchodilation therapy.

  2017cites this paper
• Prevention Strategies for Exacerbations of Chronic Obstructive Pulmonary Disease

  2017cites this paper
• Long‐acting beta2‐agonists versus long‐acting muscarinic antagonists in patients with stable COPD: A systematic review and meta‐analysis of randomized controlled trials

  2017cites this paper
• Individualizing the selection of long-acting bronchodilator therapy for patients with COPD: considerations in primary care

  2017cites this paper
• Discovering the Relative Efficacy of Inhaled Medications for Chronic Obstructive Pulmonary Disease: Multiple Treatment Comparisons

  2017cites this paper
• CTS position statement: Pharmacotherapy in patients with COPD—An update

  2017cites this paper
• Safety of inhaled long-acting anti-muscarinic agents in COPD

  2017cites this paper
• Fixed-dose combination inhalers compared to long-acting bronchodilators for COPD: a network meta-analysis

  2017cites this paper
• LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment

  2017cites this paper
• Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study

  2017cites this paper
• How Do Dual Long‐Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?

  2017cites this paper
• [The effects of inhaled steroids withdrawal in COPD].

  2017cites this paper
• Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological Treatment of Stable Phase.

  2017cites this paper
• Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review

  2017cites this paper
• Effectiveness and safety of concurrent beta-blockers and inhaled bronchodilators in COPD with cardiovascular comorbidities

  2017cites this paper
• The 2017 Update to the COPD Foundation COPD Pocket Consultant Guide.

  2017cites this paper
• The place of combined bronchodilators LAMA/LABA in chronic obstructive lung disease therapy

  2017cites this paper
• Spanish COPD Guidelines (GesEPOC) 2017. Pharmacological Treatment of Stable Chronic Obstructive Pulmonary Disease

  2017cites this paper
• Effect of a short term pulmonary rehabilitation programme on exercise capacity, pulmonary function and health related quality of life in patients with COPD

  2017cites this paper
• A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β2-Agonist (LABA) Combinations in COPD

  2017cites this paper
• Cardiac effects of current treatments of chronic obstructive pulmonary disease.

  2016cites this paper
• First year of the thoracic triumvirate

  2016cites this paper